Aging is becoming programmable.
What’s happening: Longevity biotech firm NewLimit raised $435M at a $3.1B valuation after reporting age reversal in human liver cells.
Fast forward. Founded by Coinbase CEO Brian Armstrong, the company is developing epigenetic reprogramming therapies designed to restore cells to a younger state, with plans to begin human trials next year.
Turn back. If successful, the approach could address metabolic dysfunction, cardiovascular disease, and immune decline by reprogramming aging biology rather than treating individual conditions.
Cash in. Fueled by advances in AI and biotech, NewLimit is the latest bet on longevity medicine, with billions flowing to Sam Altman-backed Retro Biosciences, recently valued at $1.8B, and Jeff Bezos-backed Altos Labs.
Takeaway: Beyond wellness routines and optimization protocols, extending healthspan is evolving from a lifestyle pursuit into a clinical reality.
